BIOMAT Database Logo BIOMAT Database Logo

Absorption studies of the H2-blocker nizatidine. 1987

M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
Lilly Research Laboratories, Lilly Laboratory for Clinical Research, Indianapolis, IN.

The absolute and relative bioavailability of nizatidine, an H2-blocker, was studied in healthy male volunteers. The absolute oral bioavailability, relative to that after intravenous administration, was 98% +/- 14%. The bioavailability of single and multiple oral doses of 150 mg nizatidine was unaffected by concurrent food ingestion; nizatidine may be administered either with or without food. The relative bioavailability of nizatidine was compared when given simultaneously with placebo or Gelusil, 30 minutes after propantheline, or 60 minutes before activated charcoal. Gelusil reduced the amount of nizatidine absorbed by about 10%, charcoal reduced it by about 30%, and propantheline did not affect it.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008276 Magnesium Hydroxide An inorganic compound that occurs in nature as the mineral brucite. It acts as an antacid with cathartic effects. Brucite,Magnesium Hydrate,Magnesium Hydroxide (Mg(OH)4),Hydrate, Magnesium,Hydroxide, Magnesium
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011413 Propantheline A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. Pro-Banthine,Probanthine,Propantheline Bromide,Bromide, Propantheline,Pro Banthine
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002606 Charcoal An amorphous form of carbon prepared from the incomplete combustion of animal or vegetable matter, e.g., wood. The activated form of charcoal is used in the treatment of poisoning. (Grant & Hackh's Chemical Dictionary, 5th ed) Activated Charcoal,Actidose,Actidose-Aqua,Adsorba,Carbomix,Charbon,CharcoAid,CharcoCaps,Charcodote,Formocarbine,Insta-Char,Kohle-Compretten,Kohle-Hevert,Kohle-Pulvis,Kohle-Tabletten Boxo-Pharm,Liqui-Char,Norit,Ultracarbon,Charcoal, Activated
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2

Related Publications

M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
Inhibition of acetylcholinesterase by the H2-receptor antagonist nizatidine.
November 1988, Journal of pharmacobio-dynamics,
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
H2 blocker delirium.
January 1995, Psychosomatics,
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
[Expiratory H2 studies in absorption disorders of the small intestine].
April 1986, Orvosi hetilap,
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
Preclinical toxicology studies with nizatidine, a new H2-receptor antagonist: acute, subchronic, and chronic toxicity evaluations.
November 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology,
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
October 1986, Hepato-gastroenterology,
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
[The status of H2-blocker therapy today].
January 1992, Wiener medizinische Wochenschrift (1946),
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
High-performance liquid chromatographic assay for nizatidine, a new H2 blocker, in human plasma and urine using disposable solid-phase extraction columns.
February 1990, Journal of chromatography,
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
Nizatidine: a new histamine receptor blocker in the treatment of active duodenal ulcers.
December 1986, The American journal of gastroenterology,
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
Effects of changing the type of H2-blocker in the treatment of H2-blocker-resistant ulcers: comparison of roxatidine acetate hydrochloride and other H2-blockers.
January 1998, The Journal of international medical research,
M P Knadler, and R F Bergstrom, and J T Callaghan, and B D Obermeyer, and A Rubin
H2-blocker modulates heart rate variability.
January 1999, Heart and vessels,
Copied contents to your clipboard!